Melatonin: Structural characterization of its non-enzymatic mono-oxygenate metabolite

Journal of Pineal Research

Volumn 35, Issue 4, 2003, Pages 269-275

  Agozzino, Pasquale ^a   Avellone, Giuseppe ^a   Bongiorno, David ^a   Ceraulo, Leopoldo ^a,b   Filizzola, Felice ^a   Natoli, Maria C ^a   Livrea, Maria A ^a   Tesoriere, Luisa ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Dipto di Chim Organ E Paterno ^*  (Italy)

Author keywords

1D and 2D nuclear magnetic resonance; Mass spectra; Melatonin; Metabolites; Structure

Indexed keywords

ACETAMIDE DERIVATIVE; FERROUS GLUCONATE; HEMOGLOBIN; HYPOCHLOROUS ACID; MELATONIN; N [2 (5 METHOXY 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL)ETHYL]ACETAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; FENTON REACTION; HORMONE STRUCTURE; MASS SPECTROMETRY; OXIDATION; PROTON NUCLEAR MAGNETIC RESONANCE;

MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MELATONIN;

EID: 0242269982     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2003.00086.x     Document Type: Article

References (40)

1. LERNER AB, CASE JD, TAKAHASHI Y et al. Isolation of melatonin the pineal gland factor that lightens the pinealocytes. J Am Chem Soc 1958; 80:2587.
2. REITER RJ. Melatonin: that ubiquitously acting pineal hormone. News Physiol Sci 1991; 6:223-227.
3. MANCHESTER LC, POEGGELER B, ALVARES FL et al. Melatonin immunoreactivity in the photosynthetic prokaryote, Rhodospirillum rubrum implication for an ancient antioxidant system. Cell Mol Biol Res 1995; 41:391-395.
4. POEGGELER B, BALZER I, HARDELAND R et al. Pineal hormone melatonin oscillates also in the dinoflagellate, Gonyaulax polydrea. Naturwissenschaten 1991; 78:268-269.
5. HATTORI A, MIGITAKA H, MASAYAKE I et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int 1995; 35:627-634.
6. DE VRIES MW, PEETERS FP. Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression. J Nerv Ment Dis 1997; 185:201-202.
7. JAN JE, O'DONNELL ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res 1996; 21:193-199.
8. GARFINKEL D, LAUDON M, NOF D et al. Improvement of sleep quality in elderly people by controlled release melatonin. Lancet 1995; 346:541-544.
9. MORGAN PJ, WILLIAMS LM. Central melatonin receptors: implication for a mode of action. Experientia 1989; 45:955.
10. LIST OF ORPHAN DRUG DESIGNATION AND APPROVAL. Office of Orphan Products Development, Food and Drug Administration, Rockville, MD, last rev August 2002.
11. NOWAK JZ, ZAWILSKA JB. Melatonin and its physiological and therapeutic properties. Pharm World Sci 1998; 20:18-27.
12. SANDYK R. Melatonin supplements for aging. Int J Neurosci 1996; 87:219-224.
13. PAPPOLLA MA, REITER RJ, BRYANT-THOMAS TK et al. Oxidative mediated neurodegeneration in Alzheimer's disease: melatonin and related antioxidants as neuroprotective agents. Curr Med Chem 2003; 3:233-243.
14. LISSONI P, MEREGALLI S, NASETTO L et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996; 53:43-46.
15. LISSONI P, BARNI S, BRIVIO F et al. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology 1995; 52:360-362.
16. BARNI S, LISSONI P, CAZZANIGA M et al. Randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995; 52:243-245.
17. ALDEGHI R, LISSONI P, BARNI SL et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994; 30:167-170.
18. REITER RJ, CARNEIRO RCG, OH CS. Melatonin in relation to cellular antioxidative defence mechanisms. Horm Metab Res 1997; 29:343-392.
19. TAN DX, CHEN LD, POEGGLER B et al. A potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
20. VIJAYALAXMI BZ, REITER RJ, SEWERYNEK E et al. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res 1995; 346:23-31.
21. LIVREA MA, TESORIERE L, D'ARPA D et al. Reaction of melatonin with lipoperxyl radicals in phospholipid bilayers. Free Rad Biol Med 1997; 23:706-711.
22. MARSHALL KA, REITER RJ, POEGGELER B et al. Evaluation of the antioxidant activity of melatonin in vitro. Free Rad Biol Med 1996; 21:307-315.
23. TURJANSKI AG, LEONIK F, ESTRIN DA et al. Scavenging of NO by melatonin. J Am Chem Soc 2000; 122:10, 468-10,469.
24. 2: evidence for a free radical mechanism. J Am Chem Soc 1999; 121:9738-9739.
25. BARCHAS J, DA COSTA F, SPECTOR S. Acute pharmacology of melatonin. Nature 1967; 214:919-920.
26. ALLEGRA M, REITER RJ, TAN DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
27. REITER RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interaction. Endocrine Rev 1991; 12:151-180.
28. VAKKURI O, TERVO J, LUTTINEN R et al. A Cyclic isomer of 2-hydroxymelatonin: a novel metabolite of melatonin. Endocrinology 1987; 120:2453-2459.
29. TAN DX, MANCHESTER LC, REITER RJ et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochim Biophys Res Commun 1998; 253:614-620.
30. DELLEGAR SM, MURPHY SA, BOURNE AE et al. Identification of the factors affecting the rate of deactivation of hypochlorous acid by melatonin. Biochem Biophys Res Commun 1999; 257:431-439.
31. TESORIERE L, AVELLONE G, CERAULO L et al. Oxidation of melatonin by oxoferryl hemoglobin: a mechanistic study. Free Radical Research 2001; 35:633-642.
32. CERAULO L, FERRUGIA M, TESORIERE L et al. Interactions of melatonin with membrane models: portioning of melatonin in AOT and Lecithin Reversed Micelles. J Pineal Res 1999; 26:108-112.
33. BONGIORNO D, CERAULO L, MELE A et al. Structural and physicochemical characterization of the inclusion complexes of cyclomaltooligosaccharides (cyclodextrins) with melatonin. Carbohydr Res 2002; 337:743-754.
34. BONGIORNO D, CERAULO L, MELE A et al. Guest-to-host-proton transfer in melatonin-beta-cyclodextrin inclusion complex by ionspray, fast atom bombardament and tandem mass spectrometry. J Mass Spectrom 2001; 36:1189-1194.
35. 2 yields persistent ferryl iron and protein based radicals. Free Radical Res Comm 1996; 22:117-123.
36. DIAMANTINI G, TARZIA G, SPADONI G et al. Metastable ion studies in the characterization of melatonin isomers. Rapid Commun Mass Spectrom 1998; 12:1538-1542.
37. th Volume: Indoles Part I. Weissberger A, Taylor EC, eds, John Wiley & Sons, New York, 1972; pp. 3-5.
38. CARDINALI DP, LADIEZESKY MG, BOGGIO V et al. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34:81-87.
39. CHEUNG TF. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 2003; 34:153-160.
40. SAHNA E, ACET A, OZER MK et al. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 2002; 33:234-238.